Concerta

Concerta is a brand name of methylphenidate, approved by the FDA in the following formulation(s):

CONCERTA (methylphenidate hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: August 1, 2000
  
  Strength(s): 18MG, 36MG
  


• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: December 8, 2000
  
  Strength(s): 54MG ^[RLD]


• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: April 1, 2002
  
  Strength(s): 27MG
  

Has a generic version of Concerta been approved?

No. There is currently no therapeutically equivalent version of Concerta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Concerta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods and devices for providing prolonged drug therapy
  Patent 6,919,373
  Issued: July 19, 2005
  Inventor(s): Lam; Andrew C. & Shivanand; Padmaja & Ayer; Atul D. & Weyers; Richard G. & Gupta; Suneel K. & Guinta; Diane R. & Christopher; Carol A. & Saks; Samuel R. & Hamel; Lawrence G. & Wright; Jeri D. & Hatamkhany; Zahedeh
  Assignee(s): Alza Corporation
  Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
  
  Patent expiration dates:
  
  
  • July 31, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING ADHD
  
  
  
  • January 31, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Methods and devices for providing prolonged drug therapy
  Patent 6,930,129
  Issued: August 16, 2005
  Inventor(s): Lam; Andrew C. & Shivanand; Padmaja & Ayer; Atul D. & Hatamkhany; Zahedeh & Gupta; Suneel K. & Guinta; Diane R. & Christopher; Carol A. & Saks; Samuel R. & Hamel; Lawrence G. & Wright; Jeri D. & Weyers; Richard G.
  Assignee(s): Alza Corporation
  Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
  
  Patent expiration dates:
  
  
  • July 31, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING ADHD
  
  
  
  • January 31, 2018
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 27, 2011 - NEW PATIENT POPULATION
  
  
  • November 4, 2012 - ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
  
  

See also...

• Concerta Consumer Information (Drugs.com)
• Concerta Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Concerta Consumer Information (Cerner Multum)
• Concerta Advanced Consumer Information (Micromedex)
• Methylphenidate Consumer Information (Drugs.com)
• Methylphenidate Consumer Information (Wolters Kluwer)
• Methylphenidate Chewable Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Solution Consumer Information (Wolters Kluwer)
• Methylphenidate System Consumer Information (Wolters Kluwer)
• Methylphenidate Consumer Information (Cerner Multum)
• Methylphenidate transdermal Consumer Information (Cerner Multum)
• Methylphenidate Oral, Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Hydrochloride AHFS DI Monographs (ASHP)